Somite, a pioneering venture in the realm of stem cell biology, has achieved a significant milestone by securing $5.3 million in pre-seed funding.
Spearheaded by Israel’s renowned venture fund, TechAviv, and bolstered by esteemed backers such as Next Coast Ventures, Trust Ventures, Texas Venture Partners, Lerer Hippeau, and others, this investment marks a pivotal moment in Somite’s journey towards revolutionizing medical innovation.
At its core, Somite endeavors to emulate the groundbreaking success of OpenAI in the domain of stem cell biology. By harnessing the power of artificial intelligence, Somite aims to address the complexities inherent in producing human tissue for cell therapies at scale. With a team of seasoned experts at its helm, including CEO Dr. Micha Breakstone and CTO Dr. Jonathan Rosenfeld, who bring a wealth of experience in AI entrepreneurship and computational biology respectively, Somite is well-positioned to drive forward its ambitious agenda.
Do you need investors for your startup?
Central to Somite’s vision is the development of the AlphaStem AI platform, a proprietary technology designed to unlock the intricacies of cell differentiation. Through the creation of a digital twin of the embryo—a computational model mirroring real embryo development—Somite leverages vast datasets to expedite the discovery of innovative protocols and optimize cell therapy production. Notably, Somite’s focus on somite-derived lineages holds promise for treating a myriad of diseases, including diabetes, obesity, and muscular dystrophies.
With acceptance into esteemed institutions like the Blavatnik Harvard Life Labs and the acquisition of groundbreaking patents, Somite has swiftly emerged as a frontrunner in the field. As CEO Micha Breakstone aptly summarizes, the convergence of AI and biology represents the future of medicine, and Somite is poised to lead the charge. This recent funding injection serves as a testament to Somite’s potential to redefine medical innovation and transform the lives of millions worldwide.
* It is a community posted article. Please read the Full Disclaimer below
Disclaimer: This post is AI-generated. Its content does not represent the views of Xstartups. Xstartups is not liable for the accuracy or implications of the content. For any concerns or copyright issue, contact us at complaint@xstartups.co.
